- Home
- PCRX vs KBDC Comparison
PCRX vs KBDC Comparison
Compare PCRX & KBDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- KBDC
- Stock Information
- Founded
- PCRX 2006
- KBDC 2021
- Country
- PCRX United States
- KBDC United States
- Employees
- PCRX N/A
- KBDC N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- KBDC
- Sector
- PCRX Health Care
- KBDC
- Exchange
- PCRX Nasdaq
- KBDC Nasdaq
- Market Cap
- PCRX 1.1B
- KBDC 1.2B
- IPO Year
- PCRX 2011
- KBDC N/A
- Fundamental
- Price
- PCRX $24.91
- KBDC $16.51
- Analyst Decision
- PCRX Buy
- KBDC Buy
- Analyst Count
- PCRX 9
- KBDC 5
- Target Price
- PCRX $30.67
- KBDC $17.30
- AVG Volume (30 Days)
- PCRX 920.6K
- KBDC 173.5K
- Earning Date
- PCRX 05-06-2025
- KBDC 03-03-2025
- Dividend Yield
- PCRX N/A
- KBDC 9.10%
- EPS Growth
- PCRX N/A
- KBDC N/A
- EPS
- PCRX N/A
- KBDC N/A
- Revenue
- PCRX $700,966,000.00
- KBDC N/A
- Revenue This Year
- PCRX $9.77
- KBDC $193.84
- Revenue Next Year
- PCRX $9.83
- KBDC $15.95
- P/E Ratio
- PCRX N/A
- KBDC N/A
- Revenue Growth
- PCRX 3.85
- KBDC N/A
- 52 Week Low
- PCRX $11.16
- KBDC $15.69
- 52 Week High
- PCRX $31.67
- KBDC $17.99
- Technical
- Relative Strength Index (RSI)
- PCRX 55.86
- KBDC N/A
- Support Level
- PCRX $23.93
- KBDC N/A
- Resistance Level
- PCRX $25.08
- KBDC N/A
- Average True Range (ATR)
- PCRX 0.97
- KBDC 0.00
- MACD
- PCRX 0.20
- KBDC 0.00
- Stochastic Oscillator
- PCRX 76.05
- KBDC 0.00
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About KBDC Kayne Anderson BDC Inc. Common Stock
Kayne Anderson BDC Inc is a business development company that invests primarily in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation primarily through debt investments in middle-market companies.